Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan to Review Moderna Vaccine with Top Priority, May OK Possible: Minister
March 8, 2021
- Pfizer, Bayer to Pull Plug on “G1” Products with High Generic Erosions
March 5, 2021
- MHLW Announces New Drug Prices for 1st Off-Year Revision in April
March 5, 2021
- Vaccine Minister Says Govt to Stick to 3 Week Interval for Now
March 4, 2021
- MHLW Weighs 6-Week Dosing Interval for Pfizer Vaccine
March 4, 2021
- Vaccine Freezer Breakdown Due to Power Shortage: MHLW
March 4, 2021
- Nichi-Iko Ordered to Suspend Biz over Sloppy Manufacturing
March 3, 2021
- All Municipalities to Get 1 Carton of COVID-19 Vaccines for Elderly in Final Week of April: MHLW
March 3, 2021
- Freezers for Moderna Vaccine Could Be Used for Comirnaty Too: Campaign Minister
March 3, 2021
- Woman Dies 3 Days after COVID-19 Vaccine Shot, but Link Indeterminable
March 3, 2021
- MHLW Unveils List of “Stable Supply Medicines”
March 2, 2021
- Nichi-Iko to Get Business Suspension Order on March 3
March 2, 2021
- MHLW Study Group Compiles Guideline for Collecting COVID-19 Convalescent Plasma
March 2, 2021
- 172 Vials of Pfizer Vaccine Unusable due to Freezer Breakdown
March 2, 2021
- MHLW Asks Municipalities to Secure Adrenaline Preparations for Anaphylaxis
March 1, 2021
- PAFSC Minutes for Pfizer Vaccine Disclosed
March 1, 2021
- Govt to Deliver 1st COVID-19 Vaccine Dose for 3.7 Million HCPs in April: Minister
March 1, 2021
- MHLW Orders Label Revisions for NSAIDs, Salbutamol, Kymriah
March 1, 2021
- Japan Research Group to Wrap Up Report on Clinical Trials for Cannabis-Derived Drugs by March-End
February 26, 2021
- Key Panel Gives Thumbs-Up to Teijin’s Osteoporosis Med, JCR’s Hunter Syndrome Drug and More
February 26, 2021
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…